Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database.
about
Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives.Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in manOptimising case detection within UK electronic health records: use of multiple linked databases for detecting liver injuryGenotyping for severe drug hypersensitivity.Penicillinase-resistant antibiotics induce non-immune-mediated cholestasis through HSP27 activation associated with PKC/P38 and PI3K/AKT signaling pathwaysDrug-Induced Liver Injury: Cascade of Events Leading to Cell Death, Apoptosis or NecrosisSafety and efficacy of the immunosuppressive agent 6-tioguanine in murine model of acute and chronic colitis.Drug-induced liver injury in older adults.Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury.Risk of acute liver injury associated with the use of moxifloxacin and other oral antimicrobials: a retrospective, population-based cohort study.Pharmacogenomics of antimicrobial agents.Genomics and drug response.Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin.Drug metabolite profiling and elucidation of drug-induced hepatotoxicity.Idiosyncratic drug-induced liver injury: an overview.Role of the bile salt export pump, BSEP, in acquired forms of cholestasis.Pharmacogenetics of drug-induced liver injury.Genetic association studies in drug-induced liver injury.Antibiotic induced liver injury: what about children?Idiosyncratic drug-induced liver injury: an update on the 2007 overview.Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review.Human leukocyte antigen genetic risk factors of drug-induced liver toxicology.Quantification of the risk of liver injury associated with flucloxacillin: a UK population-based cohort study.Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury.Genetic Factors Influencing Drug-Induced Liver Injury: Do They Have a Role in Prevention and Diagnosis?Updated study on risk of cholestatic liver disease and flucloxacillin.Severe hepatotoxic adverse reaction in a healthy schoolgirl after treatment with flucloxacillin.A role for the pregnane X receptor in flucloxacillin-induced liver injury.Drug-induced liver injury in the Australian setting.Dissecting the molecular pathophysiology of drug-induced liver injury.Involvement of immune- and inflammatory-related factors in flucloxacillin-induced liver injury in mice.Drug Induced Hypersensitivity and the HLA Complex.Personalized medicine for HLA-associated drug-hypersensitivity reactionsPharmacogenetics of Adverse Drug Reactions
P2860
Q27690772-955A1264-A625-46C2-B8EF-F22C6FF18018Q28069617-5A446D76-8093-466A-8934-3CEBE7C066F6Q28595842-1FE77258-6CD1-4CDD-B5A4-534EC2418A75Q33582530-2B376353-7394-4FFE-9BBB-DC3B42600BE4Q33687525-D6F538F0-9074-432D-B700-F5E43EB85BDEQ33755165-75621B74-2E0F-42AD-AC87-0BE1A888263AQ33890504-921E84A9-A48F-421B-814A-F32166E7470CQ33949227-7D4C803F-BD74-4CE0-92CB-EB5D346A5832Q34342305-092374D0-34BA-4294-98E8-7FC25C77A4BBQ34658795-E55EEB26-1B38-4FBF-90AA-6027B32A4A6FQ34977413-221C7E18-D81B-49EA-91DE-FD70B6BE133DQ35252277-252C7A23-FC4B-42D6-AF75-6E4D4FF591E1Q36094911-94E8E36C-16C8-4DA2-B530-464E6E353C1AQ36835826-5B0CD0E5-763F-4684-8902-E03B0907B377Q36984240-2B53D515-9A7C-4A25-BD5A-2A0D510983A7Q37661069-8BEA3EFD-8BC3-4977-A843-F5C46E09B6F4Q37770487-27931AB5-5742-4AF1-9ACD-3196EE5F2A37Q37931275-6968B61E-8B32-4ADD-ABC4-F1B2F76CBEA5Q38144140-69A7A305-C902-4D84-AF9B-930AFB300208Q38145274-1E38B096-E9FF-43D7-A290-9715DF1FC065Q38207944-E8ADFEF1-279A-45CA-8C71-9F4D09A10272Q38285818-84B0C6CD-56A7-490F-A254-ED4DDB811F55Q38599575-EDE1B57D-D7FA-4CC4-AFAF-A4422E48ACB1Q41051252-6DF9F6C7-15CA-4254-973D-A45B90BD97DCQ41389082-F1C74A68-571F-43BF-AB51-92AF11CDBD66Q42592240-662EBD36-574B-443C-A250-2552DC8953ACQ42731715-C84FB4E4-7E26-4241-8A24-7AAAD760AFC3Q43133926-8E976C56-ABD9-427F-82A6-985687FF825AQ43424045-1FD33DB1-27CA-452D-AA5E-CE618A48E557Q52720493-A458879B-47C6-4E85-B975-0B40F3E4AADBQ54216981-BF3E7CF1-96C1-4953-9CAB-E15E489ADBD3Q55564369-43869154-8DD6-45EC-8ED3-771610E1D358Q57223243-39CF0700-291C-4208-B79A-3D258D206CF6Q57302676-09F0B330-1577-4250-BBA9-A6924B90E91C
P2860
Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Risk of cholestatic liver dise ...... al Practice Research Database.
@ast
Risk of cholestatic liver dise ...... al Practice Research Database.
@en
type
label
Risk of cholestatic liver dise ...... al Practice Research Database.
@ast
Risk of cholestatic liver dise ...... al Practice Research Database.
@en
prefLabel
Risk of cholestatic liver dise ...... al Practice Research Database.
@ast
Risk of cholestatic liver dise ...... al Practice Research Database.
@en
P2860
P1476
Risk of cholestatic liver dise ...... al Practice Research Database.
@en
P2093
James A Kaye
Stefan Russmann
P2860
P356
10.1111/J.1365-2125.2005.02370.X
P407
P577
2005-07-01T00:00:00Z